An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ENDRA Life Sciences to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 2:00 p.m. Eastern Time. Management will also hold virtual one-on-one meetings with investors throughout the day. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization comparable to MRI, initially targeting liver fat measurement for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). For further details, visit www.endrainc.com.
Positive
None.
Negative
None.
ANN ARBOR, Mich.--(BUSINESS WIRE)--
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021. Management will deliver a company presentation at 2:00 p.m. Eastern Time and will be available for virtual one-on-one meetings with investors throughout the day.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
When will ENDRA Life Sciences present at the NASH Investor Conference?
ENDRA Life Sciences will present on October 12, 2021, at 2:00 p.m. Eastern Time.
What technology does ENDRA Life Sciences focus on?
ENDRA Life Sciences focuses on Thermo Acoustic Enhanced UltraSound (TAEUS®) technology for cost-effective tissue visualization.
What medical conditions does TAEUS® technology aim to address?
TAEUS® technology primarily targets the measurement of liver fat to assess Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
What is the significance of the H.C. Wainwright NASH Investor Conference for ENDRA Life Sciences?
The conference provides ENDRA Life Sciences an opportunity to present its innovative technology and engage with investors.
How can investors learn more about ENDRA Life Sciences?
Investors can learn more about ENDRA Life Sciences by visiting their website at www.endrainc.com.
